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Heterogeneous clinical responses to histone deacetylase inhibitors (HDACi) in diffuse large B-cell
lymphoma (DLBCL) have prompted a need for evaluating the impact of mutations in the histone acetyl
transferases (HAT) CREBBP and EP300 on HDACi treatment outcome. We identiﬁed four DLBCL cell lines;
Toledo, with mutations in CREBBP and EP300, SUDHL-7 with mutation of CREBBP and wild-type (wt)
EP300, RL with mutation of EP300 and wt CREBBP, and U2932 with wt CREBBP and wt EP300. Vorinostat
treatment induced apoptosis signiﬁcantly more rapid and profound in the CREBBP/EP300 double mutant
cell line. Our results suggest that pre-treatment stratiﬁcation according to HAT defects may be relevant
in DLBCL.
& 2012 Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction
By catalyzing post-translational acetylation of lysine residues,
the histone acetyl transferases (HAT) CREBBP and EP300moderate
the activities of both histone and non-histone proteins. This
regulates vital cellular processes such as cell cycling and apopto-
sis by modulating chromatin structure and by altering the activity
of transcription factors.1 The roles of CREBBP and EP300 in the
pathogenesis of leukemia and malignant lymphomas have
recently been highlighted.2,3 CREBBP and EP300 belong to one of
three HAT families based on their catalytic domains. They are
capable of acetylating the lysine residues of all 4 core histones as
well as over 70 other proteins.4,5
It has been shown that acetylation of the tumor suppressor
protein p53 leads to its activation, while acetylation of onco-protein
BCL6 leads to its functional inactivation.6 In germinal center B-cells
BCL6 inhibits transcription of p53 and p53 mediated apoptosis,
which allows the cells to tolerate DNA strand breaks during
immunoglobulin class switch recombination and somatic hypermu-
tation that are necessary for normal B-cell maturation. This impliesatology, Roskilde University
ark. Tel.: þ45 26122840;
sen).
.
-NC-ND license.that loss-of-acetylationmay contribute to lymphomagenesis by BCL6
over-expression and p53 inactivation, which will allow for the
survival of germinal center cells with aberrant chromosomal breaks.7
Interestingly, acetylation of BCL6 hinders its ability to recruit
histone deacetylases (HDACs) to transcription start sites; thereby
hindering HDAC mediated transcriptional repression of its target
genes.
The HDAC inhibitor (HDACi) vorinostat (suberoylanilidehy-
droxamic acid) inhibits the enzymatic activity of HDAC1, HDAC2,
HDAC3 (Class I) and HDAC6 (Class II) and therefore show multiple
effects of various proteins.
CREBBP mutations have been identiﬁed in DLBCL (39%) and
follicular lymphoma (FL) (41%), EP300 mutations being found in
10% of the same DLBCLs and in 8.7% of FL samples, respectively.3
Due to 490% sequence similarity within the two genes, they have
been suggested to be functionally homologous8; however, co-
existing alterations of both CREBBP and EP300 were found in only
6/72 cases.3 For both genes, a clustering of mutations was observed
in the catalytic HAT domains. HAT domain mutant proteins had lost
their acetyl transferase activity, while no signiﬁcant effects were
observed when mutations were located outside the HAT domain.
While the acetylation activity of the individual mutations was
thoroughly described, the consequences for cell survival were not
analyzed and is thus the focus of this study.
A direct comparison of HDACi induced apoptosis in DLBCL
cells with single vs. double mutated vs. wt CREBBP/EP300 genes
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physiologically important function of acetylation in the regulation
of apoptosis in germinal center cells and in B-cell lymphomagen-
esis, we speculated whether different responses to vorinostat
could be observed in B-cell tumors with and without CREBBP/
EP300 mutations.
In phase I and II trials, NHL patients treated with vorinostat have
exhibited heterogeneous clinical responses. Here we present experi-
mental data suggesting that vorinostat-induced apoptosis in HAT
mutant DLBCL cell lines may serve as a comparable endpoint when
drawing parallels to results from these clinical trials.2. Materials and methods
2.1. Mutation scanning
We designed a mutation screening assay based on the high-
resolution melting analysis (HRM), and subsequently veriﬁed var-
iant HRM curves by the use of denaturing gradient gel electrophor-
esis (DGGE) and direct sequencing that covered the genomic regions
that encode the catalytic domains as described.9 Sanger sequencing
of aberrant DGGE bands was performed with non-clamped primers
by the service of Euroﬁnss (www.euroﬁns.de).
When the goal of identifying the concomitant EP300/CREBBP
mutated DLBCL cell line (Toledo) and the EP300 mutated/CREBBP
wt cell line (RL) was achieved, we drew advantage from the
results by Pasqualucci and colleagues who demonstrated SUDHL-
7 to harbor two loss-of-function mutations of CREBBP, and to be
EP300 wt. In addition, they proved U2932 to be CREBBP/EP300 wt,
both by direct sequencing of whole-genome ampliﬁed DNA. These
cell lines were obtained from the authors.
2.2. Treatment with vorinostat
The cell lines were incubated in the absence or presence of
vorinostat in increasing concentrations (0.1, 1.0, 2.5 mM), andFig. 1. (a) An altered HRM curve for the Toledo cell line (marked by red curves) demons
of the Toledo cell line in exon 28 of the EP300 gene (G–4C transversion resulting in a
causing a frame shift of the Toledo cell line in exon 30 of the CREBBP gene (resulting
mutation in the RL cell line in exon 26 of the EP300 gene (A–4G transition resulting in
this ﬁgure, the reader is referred to the web version of this article.)DMSO for 48 h. Vorinostat was re-added to cell cultures at 24 h.
Apoptosis assay by Annexin V/FITC and propidium iodide (PI) (BD
Pharmingen) was performed to evaluate the effect of the dosages
of vorinostat on early and late apoptosis, respectively. All apop-
tosis assays were performed in triplicates.
2.3. Statistics
The level of apoptosis between the cell lines was compared
using one-way Analysis Of Variance (ANOVA). All P-values were
two-sided. Conﬁdence limits given in ﬁgures were 95% conﬁ-
dence. SPSS version 19 was used for calculations (2010, IBM,
Somer, NY, USA).3. Results
Screening of the Toledo cell line revealed a single base change
of the EP300 gene (Fig. 1a,b). Furthermore, we identiﬁed a 3 bp
deletion of the Toledo CREBBP gene (Fig. 1c). Screening of RL
revealed a missense mutation in EP300 (Fig. 1d). The SUDHL-7
harbors two CREBBP mutations both with deleterious effects key
to HAT activity as assessed by in vivo acetylation assays in mice
(exon 26: Y1450C and exon 30: DS1680).3
3.1. Cell line apoptosis assays
We observed dose dependent increases in the fraction of
apoptotic cells in all cell lines. Statistically signiﬁcant differences
in the fraction of apoptotic cells between wt, single mutant, and
double mutant cell lines were observed in all but the lowest
concentration of vorinostat: 1 mM vorinostat (early apoptosis:
Po0.0001, late apoptosis: Po0.0001) and 2.5 mM vorinostat
(early apoptosis: P¼0.011, late apoptosis Po0.0001), respec-
tively. Interestingly, the CREBBP/EP300 double mutant Toledo cell
line exhibited a particular profound apoptosis, when compared to
the other cell lines (Fig. 2).trates the ﬁrst screening step. (b) Direct sequencing revealed a missense mutation
n amino acid substitution, L1520V). (c) Direct sequencing revealed a 3 bp deletion
in a premature stop-codon V1742X). (d) Direct sequencing revealed a missense
an amino acid substitution, Y1413C). (For interpretation of the reference to color in
Fig. 2. Comparison of induction of apoptosis through propidium iodide staining at 48 h of vorinostat treatment. Bars show 95% CI for the mean.
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Heterogeneous responses have been reported from clinical phase
I and II trials of vorinostat in NHL-patients. These data strongly
imply that diverse underlying molecular defects in these various
tumor types determine the responses to vorinostat. Mutations in the
HAT domain proteins are obvious candidates. While experimental
data show that HAT mutations did not seem to affect the effective-
ness of apoptosis induction by vorinostat in T-ALL cells,2 our data
imply that tumors with concomitant mutations of CREBBP and
EP300may be particularly sensitive to vorinostat induced apoptosis.
Given the important role of acetylation in the physiological regula-
tion of BCL6 and p53 activity in germinal center cells, CREBBP/EP300
double mutant cells are likely to have a particularly skewed BCL6/
p53-balance, leading to increased cell survival.
A plausible theory for the efﬁcacy of HDACi in HAT mutant
DLBCL is, that reestablishment of the physiological balance between
acetylation and deacetylation in HAT-deﬁcient cells by the use of
HDACi, may lead to increased p53 activation and increased apopto-
sis. Indeed, the double-mutated Toledo cell line exhibited a swift
and ultimately more profound degree of apoptosis in comparison
with both wild type and single CREBBP/EP300 mutated cell lines.
Evidence of a variant induction of apoptosis to vorinostat in
different DLBCL cell lines according to HAT mutational status
implies that defects in CREBBP/EP300 could potentially explain the
heterogeneous observations in clinical trials of vorinostat in NHL.
These ﬁndings, however, need to be conﬁrmed in future clinical
studies. The efﬁcacy of HDACi in HAT-mutation stratiﬁed DLBCL
may be further optimized by testing the numerous different
HDACi considering their different target speciﬁcities.Acknowledgments
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